三种用药方案治疗社区获得性肺炎的成本-效益分析

Cost-effectiveness of Three Kinds of Therapeutic Schemes in the Treatment of Community-acquired Pneumonia

目的分析3种用药方案治疗社区获得性肺炎(CAP)的成本-效益。方法选取2012年在本院住院的CAP患者78例,将其按照就诊时间分为3组,Ⅰ组28例、Ⅱ组26例、Ⅲ组24例。Ⅰ组给予美洛西林钠治疗,Ⅱ组给予美洛西林舒巴坦钠治疗,Ⅲ组给予头孢美唑治疗。疗程均为1周,分析3组药物经济学成本-效益。结果 3种疗效、细菌清除率及不良反应发生率比较,差异均无统计学意义(P>0.05);Ⅱ组成本-效益比低于Ⅰ组和Ⅲ组(P<0.05)。结论 3种用药方案中美洛西林舒巴坦钠静脉滴注为治疗CAP的较佳方案。

Objective To analyze the cost - effectiveness of three kinds of therapeutic schemes in the treatment of community - acquired pneumonia. Methods 78 patients with community - acquired pneumonia were selected in 2012 in our hospital, they were divided into 3 groups according to the treatment time stratified random method, I group of 28 patients, ]I group of 26 cases, m 24 cases according to different treatment options. I group was given mezlocillin sodium treatment, ]] group was given mezlocillin sodium treatment shu ba, III group was given cefmetazole treatment. All course for 1 week, phar- macoeconomics cost - effectiveness of three groups were analyzed. Results The effect, bacterial clearance rate and incidence of adverse reactions in three groups were compared, the difference were not statistically significant （ P 〉 0. 05 ） ; The cost - effec- tiveness of ]] group were lower than that of I and ]II group （P 〈 0. 05 ）. Conclusion Mezlocillin sodium intravenous drip in the three regimen is a better solution for the treatment of community - acquired pneumonia.